The Chartis System is a proprietary pulmonary assessment tool that enables physicians to identify those patients likely to respond to the Pulmonx Zephyr valves with a high degree of confidence.
The Chartis System provides precise flow and pressure readings for specific lobes in the lungs to assess collateral ventilation. Clinical studies have shown that patients with low to no collateral ventilation respond best to Zephyr valve therapy.
Chartis is an excellent idea for helping us find the right patient population.“
The introduction of Chartis has been the most important milestone in patient selection when it comes to endoscopic valve treatment.“
Using the Chartis System in combination with the StratX Lung Analysis Platform, physicians can correctly identify Zephyr valve responders in approximately 90%1 of cases.
Using the Chartis System to accurately assess collateral ventilation (CV) within the targeted treatment area, physicians can identify which patients are appropriate for the Zephyr valve therapy.
Collateral ventilation (CV+)
Expiratory airflow persists over time, indicating the presence of collateral airflow from adjacent lung compartments.
No collateral ventilation (CV-)
Expiratory airflow in the lung compartment is reduced over several breathing cycles, indicating little to no collateral airflow from adjacent lung compartments.
1 Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.
2 Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.
|CHR-CO-200*||Chartis Pulmonary Assessment System – Console|
|CHR-CO-100||Chartis Pulmonary Assessment System – Console|
|CHR-CA-12.0||Chartis Pulmonary Assessment System – Catheter|
|CHR-CA-12.0-XL||Chartis Pulmonary Assessment System – Catheter XL|
Note: The Chartis System consists of a disposable balloon catheter and console.
*The CHR-CO-200 console is not available in all markets.